Patents by Inventor Yihan Wang

Yihan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION METHOD FOR DEUTERATED MACROCYCLIC COMPOUND
    Publication number: 20220024908
    Abstract: Provided are a compound as represented by formula (D) and a preparation method therefor, where X2 is a halogen, Pg is selected from H and an amino protecting group, such as Cbz, Boc, Fmoc, Alloc, Teoc, methoxycarbonyl or ethoxycarbonyl. Also provided are a synthesized intermediate compound of the formula (D) compound and a preparation method for the intermediate compound.
    Type: Application
    Filed: November 27, 2019
    Publication date: January 27, 2022
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF
    Publication number: 20220017539
    Abstract: The present disclosure provides a substituted pyrazolo[1,5-a]pyridine compound, a composition including the same, and a use thereof. The substituted pyrazolo[1,5-a]pyridine compounds is a compound represented by formula (I) or the tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof. The compound of the present disclosure and composition thereof are useful for treating RET kinase-mediated diseases or conditions and have more excellent pharmacokinetic properties.
    Type: Application
    Filed: December 3, 2019
    Publication date: January 20, 2022
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren
  • DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF
    Publication number: 20210386737
    Abstract: A dihydroimidazopyrazinone compound, a composition including the same, and a use thereof. The dihydroimidazopyrazinone compound is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound and the composition thereof can be used to treat a proliferative disease regulated by RAS/RAF/MEK/ERK kinase and have excellent pharmacokinetic properties.
    Type: Application
    Filed: September 30, 2019
    Publication date: December 16, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren
  • Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors
    Patent number: 11186578
    Abstract: A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation, compositions, and uses thereof are disclosed. In particular, compounds of formula (I) and (II), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. Compounds disclosed herein are substituted pyrrolo[3,2-d]pyrimidines and are selective irreversible inhibitors of Bruton's tyrosine kinase. The described compounds can therefore be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: November 30, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Qingfeng Xing
  • Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
    Patent number: 11147802
    Abstract: Provided are a substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof; said substituted oxadiazole chemical compound is the oxadiazole chemical compound as represented by formula (I), or its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvent compound. The disclosed substituted oxadiazole chemical compound and composition containing said chemical compound are capable of inhibiting indoleamine 2,3-dioxygenase; it also has better pharmacokinetic parameter attributes and is capable of improving the drug concentration of the chemical compound in an animal body, thus improving the therapeutic efficacy and safety of the drug.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: October 19, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF
    Publication number: 20210283132
    Abstract: The present invention provides a diarylpyrazole compound, a composition comprising same, and a use thereof. The diarylpyrazole compound refers to the compound represented by a formula (I) or a tautomer, a stereoisomer, a prodrug, a crystalline form, a pharmaceutically acceptable salt thereof, a hydrate, or a solvent compound. The compound and the composition of the present invention can be used for treating BRAF kinase mutant proliferative diseases and have better pharmacokinetic properties.
    Type: Application
    Filed: July 9, 2019
    Publication date: September 16, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Zhiqiang Liu
  • ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY
    Publication number: 20210284646
    Abstract: Provided is an alkynyl(hetero)aromatic compound having an inhibitory effect to protein tyrosine kinase, a pharmaceutical composition comprising same, preparation and usage thereof. Specifically, disclosed is an alkynyl(hetero)aromatic compound as shown in formula (I), wherein rings A, R1, R2, R3, R4, R5, L, and B are defined in the description, a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotopic variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases, such as anti-tumor.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 16, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Qingfeng Xing
  • Benzimidazole compounds as c-Kit inhibitors
    Patent number: 11117883
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Ariad Pharmaceuticals, Inc.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
  • Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
    Patent number: 11111233
    Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: September 7, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
  • ALKYNYL (HETERO) AROMATIC RING COMPOUNDS USED FOR INHIBITING PROTEIN KINASE ACTIVITY
    Publication number: 20210269448
    Abstract: Disclosed are alkynyl (hetero) aromatic ring compounds that inhibit protein tyrosine kinases, pharmaceutical compositions comprising same, preparations therefor and uses thereof. Specifically, disclosed are an alkynyl (hetero) aromatic ring compound represented by formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form, a prodrug or an isotope variant thereof. The disclosed compounds may be used in the treatment and/or prevention of diseases associated with protein tyrosine kinase, such as in preventing tumors.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 2, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
  • (Hetero)arylamide compound for inhibiting protein kinase activity
    Patent number: 11091462
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: August 17, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • SUBSTITUTED OXADIAZOLE CHEMICAL COMPOUND AND COMPOSITION CONTAINING SAID CHEMICAL COMPOUND AND USE THEREOF
    Publication number: 20210186933
    Abstract: Provided are a substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof; said substituted oxadiazole chemical compound is the oxadiazole chemical compound as represented by formula (I), or its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvent compound. The disclosed substituted oxadiazole chemical compound and composition containing said chemical compound are capable of inhibiting indoleamine 2,3-dioxygenase; it also has better pharmacokinetic parameter attributes and is capable of improving the drug concentration of the chemical compound in an animal body, thus improving the therapeutic efficacy and safety of the drug.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 24, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY
    Publication number: 20210171542
    Abstract: A di(hetero)aryl macrocyclic compound having an inhibitory effect on protein kinase activity, preparation therefor and the use thereof. Specifically, disclosed are a di(hetero)aryl macrocyclic compound represented by formula (I), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug or an active metabolite thereof a pharmaceutical composition comprising said compound and the derivative thereof, and methods for using same, including methods for treating cancers, pain, neurological diseases, autoimmune diseases and inflammation.
    Type: Application
    Filed: April 10, 2019
    Publication date: June 10, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY
    Publication number: 20210171517
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.
    Type: Application
    Filed: November 16, 2020
    Publication date: June 10, 2021
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Aminothiazole compounds as c-Kit inhibitors
    Patent number: 11001580
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 11, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
    Patent number: 10995103
    Abstract: A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 4, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20210107906
    Abstract: Provided are pharmaceutical compositions comprising substituted pyrazolo[1,5-a]pyrimidine compounds and the use thereof. The compositions may comprise the substituted pyrazolo[1,5-a]pyrimidine compound or a pharmaceutically acceptable salt, prodrug, hydrate or solvate, polymorph, stereoisomer or isotopic variant thereof, and can be used for treating diseases treatable with Trk kinase inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 15, 2021
    Inventors: Yihan WANG, Jiuyang ZHAO
  • NOVEL ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
    Publication number: 20210093650
    Abstract: The present invention relates to a compound of a novel antiviral nucleoside reverse transcriptase inhibitor, a pharmaceutical composition containing the compound, and preparation and application of the compound. Specifically, disclosed in the present invention are a fused pyrimidine compound as represented by formula (I) and a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotopic derivative of the compound. The compound of the present invention can be used for treatment and/or prevention of infectious diseases caused by viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV).
    Type: Application
    Filed: December 4, 2018
    Publication date: April 1, 2021
    Inventors: Yihan Wang, Jiuyang Zhao
  • SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND A COMPOSITION CONTAINING THE COMPOUND AND USE THEREOF
    Publication number: 20210094939
    Abstract: A substituted amino heterocyclic carboxamide compound as represent by formula (?), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotopic variant of the compound, and a pharmaceutical composition thereof, and the use thereof as an FLT3/AXL kinase inhibitor for treating acute myelocytic leukemia.
    Type: Application
    Filed: March 28, 2019
    Publication date: April 1, 2021
    Inventors: Yihan Wang, Huanyin Li
  • DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY
    Publication number: 20210087213
    Abstract: Disclosed are a dianilinopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.
    Type: Application
    Filed: December 12, 2018
    Publication date: March 25, 2021
    Inventors: Yihan Wang, Huanyin Li